Profile data is unavailable for this security.
About the company
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.
- Revenue in USD (TTM)0.00
- Net income in USD-83.74m
- Incorporated2018
- Employees49.00
- LocationTyra Biosciences Inc2656 State StreetCARLSBAD 92008United StatesUSA
- Phone+1 (619) 728-4760
- Fax+1 (302) 655-5049
- Websitehttps://tyra.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perspective Therapeutics Inc | -1.87m | -49.02m | 747.77m | 116.00 | -- | 2.19 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 763.55m | 267.00 | -- | -- | -- | 2.02 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| IGM Biosciences Inc | 2.92m | -219.84m | 764.02m | 198.00 | -- | 9.70 | -- | 261.83 | -3.65 | -3.65 | 0.0484 | 1.33 | 0.0075 | -- | -- | 13,026.79 | -56.45 | -44.66 | -63.54 | -48.20 | -- | -- | -7,534.03 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Exscientia PLC (ADR) | 27.05m | -166.78m | 770.36m | 483.00 | -- | 1.99 | -- | 28.48 | -1.31 | -1.31 | 0.2129 | 3.00 | 0.042 | -- | 26.88 | 56,008.21 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| BIOAGE Labs Inc | 0.00 | -62.16m | 774.57m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 775.88m | 40.00 | -- | 5.98 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 785.31m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Silence Therapeutics plc | 23.04m | -51.60m | 818.42m | 115.00 | -- | 5.43 | -- | 35.53 | -0.4149 | -0.4149 | 0.184 | 1.03 | 0.1273 | -- | 2.56 | 200,320.30 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Tyra Biosciences Inc | 0.00 | -83.74m | 821.29m | 49.00 | -- | 2.37 | -- | -- | -1.61 | -1.61 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -27.06 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Dianthus Therapeutics Inc | 5.37m | -67.09m | 821.32m | 53.00 | -- | 2.41 | -- | 153.06 | -2.49 | -2.49 | 0.1968 | 11.51 | 0.0196 | -- | 3.13 | 101,245.30 | -24.54 | -41.40 | -25.91 | -44.70 | -- | -- | -1,250.32 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Immunome Inc | 10.78m | -262.59m | 825.90m | 55.00 | -- | 3.14 | -- | 76.59 | -5.64 | -5.64 | 0.2591 | 4.23 | 0.0639 | -- | -- | 196,072.70 | -155.54 | -94.54 | -193.54 | -112.66 | -- | -- | -2,435.02 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Zenas Biopharma Inc | 50.00m | -54.76m | 846.38m | 114.00 | -- | -- | -- | 16.93 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -220.01m | 854.02m | 331.00 | -- | 2.00 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Capricor Therapeutics Inc | 27.15m | -27.95m | 874.31m | 101.00 | -- | 54.33 | -- | 32.20 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Erasca Inc | 0.00 | -158.28m | 878.59m | 126.00 | -- | 1.88 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Tyra Biosciences Inc's reporting currency: US Dollar USD
43.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 18 Oct 2024 | 9.42m | 17.83% |
| BVF Partners LPas of 30 Jun 2024 | 4.66m | 8.83% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 3.35m | 6.34% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.31m | 2.48% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.20m | 2.27% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 1.01m | 1.91% |
| Sio Capital Management LLCas of 30 Jun 2024 | 600.29k | 1.14% |
| Kynam Capital Management LPas of 30 Jun 2024 | 566.72k | 1.07% |
| Geode Capital Management LLCas of 30 Jun 2024 | 522.67k | 0.99% |
| Avidity Partners Management LPas of 30 Jun 2024 | 373.00k | 0.71% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
